Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | G6PD | P11413 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8008016 | 0.95 | PTGS1 (0.59) | LMNAPTGS1PTGS2CYP19A1ALOX5 | |
| SCHEMBL10165092 | 0.87 | TSHR (0.65) | LMNAPTGS1PTGS2CYP19A1ALOX5 | |
| SCHEMBL11288666 | 0.87 | MAPT (0.57) | LMNAPTGS1PTGS2CYP19A1ALOX5 | |
| SCHEMBL1689643 | 0.86 | LMNA (0.49) | LMNAPTGS1PTGS2CYP19A1ALOX5 | |
| SCHEMBL2842859 | 0.86 | LMNA (0.49) | LMNAPTGS1PTGS2CYP19A1ALOX5 | |
| SCHEMBL16954027 | 0.86 | LMNA (0.49) | LMNAPTGS1PTGS2CYP19A1ALOX5 | |
| SCHEMBL4824913 | 0.86 | LMNA (0.49) | LMNAPTGS1PTGS2CYP19A1ALOX5 | |
| SCHEMBL189811 | 0.86 | MAPT (0.56) | LMNAPTGS1PTGS2HTTMEN1 | |
| SCHEMBL4971995 | 0.86 | MEN1 (0.49) | LMNAPTGS1PTGS2ALOX5HTT | |
| SCHEMBL282545 | 0.86 | LMNA (0.49) | LMNAPTGS1PTGS2CYP19A1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4473713-A | Hydrolysis of aryl-aliphatic ethers | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-09-25 | — | — | US | claimed |
| US-20230255995-A1 | Nicotinyl Riboside Compounds and Their Uses | MITOPOWER LLC | 2023-08-17 | — | — | US | disclosed |
| EP-3986420-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | Mitopower LLC (US) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020257283-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | MITOPOWER LLC (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200397807-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | MITOPOWER LLC | 2020-12-24 | — | — | US | disclosed |
| US-20170252347-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | MITOCHON PHARMACEUTICALS, INC. | 2017-09-07 | — | — | US | disclosed |
| CN-105295958-A | Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display element | CHI MEI CORP | 2016-02-03 | — | — | CN | disclosed |
| CN-105273724-A | Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display element | CHI MEI CORP | 2016-01-27 | — | — | CN | disclosed |
| CN-103889944-A | Photoalignment material | ROLIC AG | 2014-06-25 | — | — | CN | disclosed |
| CN-103702970-A | photoalignment material | ROLIC AG | 2014-04-02 | — | — | CN | disclosed |
| WO-1996009285-A1 | IODINATED X-RAY-CONTRAST MEDIA | NYCOMED IMAGING AS (NO) | 1996-03-28 | — | — | WO | disclosed |
| US-5500060-A | IMPROVED SAFETY RELATED TO UNWANTED IGNITION, NITRAMINE COMPOUNDS, AROMATIC NITRO COMPOUNDS | ROYAL ORDNANCE PLC (GB) | 1996-03-19 | — | — | US | disclosed |
| US-5037640-A | Protective coating against ultraviolet radiation | CLAIROL INCORPORATED (US) | 1991-08-06 | — | — | US | disclosed |
| US-4473713-A | Hydrolysis of aryl-aliphatic ethers | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-09-25 | — | — | US | disclosed |
| US-4281151-A | ANTIALLERGENS, ANTIANAPHYLACTIC AGENTS | THE UPJOHN COMPANY (US) | 1981-07-28 | — | — | US | disclosed |
| US-4186127-A | ANTIALLERGENS | THE UPJOHN COMPANY (US) | 1980-01-29 | — | — | US | disclosed |
| US-4095028-A | PROPHYLAXIS, ALLERGIES | THE UPJOHN COMPANY (US) | 1978-06-13 | — | — | US | disclosed |
| US-4089973-A | Cyano phenylene dioxamic acid compounds used in the treatment of allergy | THE UPJOHN COMPANY (US) | 1978-05-16 | — | — | US | disclosed |
| US-3993679-A | ANTIALLERGY | THE UPJOHN COMPANY (US) | 1976-11-23 | — | — | US | disclosed |
| US-3969413-A | Hydroformylation process using catalyst comprising cobalt and polynitroaryl compounds | UNIVERSAL OIL PRODUCTS COMPANY (US) | 1976-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397807-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | NADK, NNT, NAMPT | LMNA 800/4885PTGS1 2133/4885PTGS2 2019/4885 |
| US-20230255995-A1 | Nicotinyl Riboside Compounds and Their Uses | NADK, NNT, NAMPT | LMNA 800/4885PTGS1 2133/4885PTGS2 2019/4885 |
| US-20170252347-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | SMN1; SMN2, MYLK2, WFS1 | LMNA 297/4885PTGS1 589/4885PTGS2 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.